Drug development for pain treatment

Immunalgia Therapeutics was created in 2019 by three renowned scientist from the National Scientific and Technical Research Council (CONICET) (Argentina).

In recent years it has been discovered that chronic pain, in addition to being processed by the nervous system and its neurons, develops together of glial cells and the immune system. The therapy proposed by Immunalgia Therapeutics has the virtue of alleviating pain, precisely by acting on these three components.

Immunalgia Therapeutics is determined to change the future of chronic pain treatment, by using a disruptive technology based on small fractions of synthetic oligonucleotides.